The potential of Sareum's SDC-1801 TYK2/JAK1 inhibitor in the fight against Covid-19

Find out more large-arrow.png


Sareum has an innovative pipeline of drug development candidates.

Find out more large-arrow.png


BioTrinity, April 2020 (Video, Slides)
Proactive Investors, March 2020 (Video)
Half-yearly Results, March 2020 (Slides)

  • @Sareumplc Latest tweet

    "TYK2 is one of the most highly anticipated MOAs in clinical development" "TYK2 represents a new class of ORAL drug… https://t.co/7D3E6aEcGJ via @Sareumplc
    View more